INTERVIEW: Oxford Biodynamics Extending precision medicine study

Oxford Biodynamics Plc (LON:OBD) Director of Business Development & Head of Statistics Dr. Ewan Hunter talks to DirectorsTalk about the publication of a paper in the Journal of Translational Medicine. Ewan provides a summary of the paper, explains the impact towards precision medicine, how this work fits into the landscape of chromosome architecture, regulation of gene expression and the control of the genome via the non-coding genome. Ewan also explains how OBD is extending this work.

Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    Potential Epigenetic Avenues for ALS Relief

    Amyotrophic lateral sclerosis (ALS), perhaps more commonly known as Lou Gehrig’s disease, is a devastating neurological disease that ultimately leads to death.  This disease eats away at nerve cells, causing death to the motor neurons in

    Oxford BioDynamics

    MND Awareness Month

    June is Motor Neurone Disease (MND) awareness month- MND describes a disease that affects the nerves in the brain and spinal cord that tell your muscles what to do. MND stops the messages from the nerves

    Oxford BioDynamics

    Benefits of Cancer Immunotherapy

    A TARGETED ANSWER TO CANCER Like many patients and caregivers on a cancer treatment journey, you may be familiar with traditional treatments such as chemotherapy and radiation. Several important features of immunotherapy make for a more

    Oxford BioDynamics

    Autism diagnosis may be possible as early as age 14 months

    Clinicians can reliably diagnose autism in some toddlers roughly two years earlier than the typical age of diagnosis, a new study suggests. The researchers assessed more than 1,200 toddlers for autism at least twice using standard

    Oxford BioDynamics

    Oxford BioDynamics Plc to present at China BIO Conference

    Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, today announced that it has been selected

    Oxford BioDynamics

    Oxford BioDynamics Plc joins ALS Biomarker study sponsored by MTPA

    Oxford BioDynamics Plc (LON: OBD), a biotechnology company focused on the discovery and development of epigenetic biomarkers based on regulatory genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to note today’s announcement

    Oxford BioDynamics

    How a diagnosis of autism can be your moment of liberation

    How I agree with Jim Cosgrove’s moving letter about the perils of classifying children and young people into categories and the desirability of an inclusive approach to all manifestations of the human experience. However, as the